PL2102331T3 - Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+ - Google Patents
Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+Info
- Publication number
- PL2102331T3 PL2102331T3 PL08701232T PL08701232T PL2102331T3 PL 2102331 T3 PL2102331 T3 PL 2102331T3 PL 08701232 T PL08701232 T PL 08701232T PL 08701232 T PL08701232 T PL 08701232T PL 2102331 T3 PL2102331 T3 PL 2102331T3
- Authority
- PL
- Poland
- Prior art keywords
- normal
- cells
- composition
- lymphoid cells
- lymphocytes
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 210000004698 lymphocyte Anatomy 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 210000001550 testis Anatomy 0.000 abstract 2
- 230000035131 DNA demethylation Effects 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
| PCT/EP2008/050050 WO2008081035A1 (fr) | 2007-01-03 | 2008-01-03 | Vaccin antitumoral dérivé de cellules normales |
| EP08701232A EP2102331B1 (fr) | 2007-01-03 | 2008-01-03 | Vaccin antitumoral dérivé de cellules cd4+ normales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2102331T3 true PL2102331T3 (pl) | 2012-01-31 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08701232T PL2102331T3 (pl) | 2007-01-03 | 2008-01-03 | Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (fr) |
| EP (1) | EP2102331B1 (fr) |
| JP (1) | JP5452231B2 (fr) |
| AT (1) | ATE522600T1 (fr) |
| AU (1) | AU2008203730B2 (fr) |
| CY (1) | CY1112668T1 (fr) |
| DK (1) | DK2102331T3 (fr) |
| ES (1) | ES2372713T3 (fr) |
| GB (1) | GB0700058D0 (fr) |
| HR (1) | HRP20110899T1 (fr) |
| PL (1) | PL2102331T3 (fr) |
| PT (1) | PT2102331E (fr) |
| SI (1) | SI2102331T1 (fr) |
| WO (1) | WO2008081035A1 (fr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200801751A1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| US8586359B2 (en) * | 2009-07-28 | 2013-11-19 | Promising Furture, LLC | Compositions and methods of preparing alloreactive cytotoxic T cells |
| JP5816627B2 (ja) | 2009-10-27 | 2015-11-18 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| KR102481922B1 (ko) | 2015-05-28 | 2022-12-28 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 진단 방법 |
| US9855298B2 (en) | 2015-05-28 | 2018-01-02 | Kite Pharma, Inc. | Methods of conditioning patients for T cell therapy |
| SG11201802966TA (en) | 2015-10-20 | 2018-05-30 | Kite Pharma Inc | Methods of preparing t cells for t cell therapy |
| CN117903307A (zh) | 2016-04-01 | 2024-04-19 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| AU2017240788B2 (en) | 2016-04-01 | 2020-04-09 | Amgen Inc. | Chimeric receptors and methods of use thereof |
| PE20190173A1 (es) | 2016-04-01 | 2019-02-01 | Kite Pharma Inc | Receptores de antigenos quimericos y celulas t y metodos de uso |
| AR110979A1 (es) | 2017-02-14 | 2019-05-22 | Kite Pharma Inc | Moléculas de unión a cd70 y métodos de uso de las mismas |
| US20180280437A1 (en) | 2017-03-13 | 2018-10-04 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| SG11201907744QA (en) | 2017-04-01 | 2019-09-27 | Avm Biotechnology Llc | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| SG11201908980PA (en) | 2017-04-03 | 2019-10-30 | Kite Pharma Inc | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| KR102426447B1 (ko) | 2017-05-26 | 2022-07-29 | 카이트 파마 인코포레이티드 | 배아 중간엽 전구 세포를 제조하고 사용하는 방법 |
| KR102521245B1 (ko) | 2017-09-15 | 2023-04-17 | 카이트 파마 인코포레이티드 | 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템 |
| CN111417652B (zh) | 2017-09-22 | 2023-10-20 | 凯德药业股份有限公司 | 嵌合多肽及其用途 |
| TW202510896A (zh) | 2017-10-18 | 2025-03-16 | 美商凱特製藥公司 | 投與嵌合抗原受體免疫療法之方法 |
| WO2019099707A1 (fr) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Récepteurs antigéniques chimériques modifiés et procédés d'utilisation |
| SG11202006416TA (en) | 2018-01-15 | 2020-08-28 | Pfizer | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist |
| US12338459B2 (en) | 2018-02-02 | 2025-06-24 | Arizona Board Of Regents On Behalf Of Arizona State University | DNA-chimeric antigen receptor T cells for immunotherapy |
| JP2021513839A (ja) | 2018-02-16 | 2021-06-03 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | 改変された多能性幹細胞並びに製造方法及び使用方法 |
| TW202322828A (zh) | 2018-04-12 | 2023-06-16 | 美商凱特製藥公司 | 利用腫瘤微環境之特性之嵌合受體ｔ細胞治療 |
| KR102734592B1 (ko) | 2018-06-01 | 2024-11-27 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| EP3810780A1 (fr) | 2018-06-22 | 2021-04-28 | Kite Pharma Eu B.V. | Compositions et procédés pour produire des lymphocytes t modifiés |
| US20200038442A1 (en) | 2018-08-02 | 2020-02-06 | Kite Pharma, Inc. | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| EP3632446B3 (fr) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Thérapies immunoablatives |
| EP3488851A1 (fr) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Thérapies immunoablatives |
| IL283734B2 (en) | 2018-12-12 | 2025-03-01 | Kite Pharma Inc | Chimeric antigen receptors and CAR-T cells and methods of use |
| US20220175900A1 (en) * | 2019-04-12 | 2022-06-09 | Cytovac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| US20200384027A1 (en) | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| KR20250095757A (ko) | 2019-06-21 | 2025-06-26 | 카이트 파마 인코포레이티드 | TGF-β 수용체 및 이의 사용 방법 |
| CN114341348A (zh) | 2019-09-03 | 2022-04-12 | 艾洛基治疗公司 | 制备用于t细胞疗法的t细胞的方法 |
| WO2021260675A1 (fr) | 2020-06-24 | 2021-12-30 | Yeda Research And Development Co. Ltd. | Agents pour sensibiliser des tumeurs solides à un traitement |
| IL299911A (en) | 2020-08-14 | 2023-03-01 | Kite Pharma Inc | Improving immune cell function |
| EP4501951A3 (fr) | 2020-08-25 | 2025-04-30 | Kite Pharma, Inc. | Lymphocytes t à fonctionnalité améliorée |
| WO2022093925A1 (fr) | 2020-10-28 | 2022-05-05 | Kite Pharma, Inc. | Méthode de cytométrie de flux pour la caractérisation d'impuretés de lymphocytes t |
| KR20230124656A (ko) | 2020-12-24 | 2023-08-25 | 카이트 파마 인코포레이티드 | 전립선암 키메라 항원 수용체 |
| EP4275044A1 (fr) | 2021-01-10 | 2023-11-15 | Kite Pharma, Inc. | Thérapie par lymphocytes t |
| EP4281545A1 (fr) | 2021-01-21 | 2023-11-29 | CytoVac A/S | Méthode d'expansion de lymphocytes t et applications médicales associées |
| JP2024507199A (ja) | 2021-02-20 | 2024-02-16 | カイト ファーマ インコーポレイテッド | 免疫療法を選択するための遺伝子マーカー |
| US12454563B2 (en) | 2021-03-11 | 2025-10-28 | Kite Pharma, Inc. | Immune cell function |
| EP4323943A1 (fr) | 2021-04-16 | 2024-02-21 | Kite Pharma, Inc. | Procédés et systèmes de planification d'une procédure d'immunothérapie spécifique à un patient |
| EP4323400A1 (fr) | 2021-04-16 | 2024-02-21 | Kite Pharma, Inc. | Molécules à liaison double taci/bcma |
| KR20230173179A (ko) | 2021-05-14 | 2023-12-26 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t세포 요법 |
| KR20240013173A (ko) | 2021-05-24 | 2024-01-30 | 카이트 파마 인코포레이티드 | Nkg2d-기초 키메라 항원 수용체 |
| AU2022291365A1 (en) | 2021-06-08 | 2024-01-18 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (fr) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Procédé de préparation de lymphocytes t cytotoxiques présentant une large réactivité spécifique aux tumeurs et des caractéristiques propres aux cellules à différenciation précoce |
| EP4363558A1 (fr) | 2021-07-01 | 2024-05-08 | Kite Pharma, Inc. | Système fermé et procédé de fabrication de thérapie cellulaire autologue et allogène |
| US20230103457A1 (en) | 2021-07-02 | 2023-04-06 | Kite Pharma, Inc. | Method for identifying variants in gene products from gene constructs used in cell therapy applications |
| EP4376876A1 (fr) | 2021-07-26 | 2024-06-05 | Kite Pharma, Inc. | Récepteurs d'antigènes chimériques divisés et méthodes d'utilisation |
| JP2024532010A (ja) | 2021-07-30 | 2024-09-04 | カイト ファーマ インコーポレイテッド | 細胞療法により誘発された毒性の監視及び管理 |
| TWI863006B (zh) | 2021-10-18 | 2024-11-21 | 美商凱特製藥公司 | 用於嵌合抗原受體之信號傳導域 |
| US20230296610A1 (en) | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
| WO2023247324A1 (fr) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Nouveau traitement combiné avec une thérapie cellulaire adoptive |
| WO2024044670A1 (fr) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Amélioration de l'activité de cellules immunitaires |
| WO2024092152A1 (fr) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Amélioration de l'efficacité et de la réponse durable de l'immunothérapie |
| EP4608987A1 (fr) | 2022-10-28 | 2025-09-03 | Kite Pharma, Inc. | Facteurs d'optimisation de l'immunothérapie |
| AU2024241240A1 (en) | 2023-03-17 | 2025-10-16 | Kite Pharma, Inc. | Impact of tumor microenvironment on efficacy of immunotherapy |
| WO2025096517A1 (fr) | 2023-11-01 | 2025-05-08 | Kite Pharma, Inc. | Facteurs pour optimiser l'efficacité d'une immunothérapie |
| US20250262300A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| US20250290154A1 (en) | 2024-03-04 | 2025-09-18 | Kite Pharma, Inc. | Predictive markers for immunotherapy |
| WO2025231376A1 (fr) | 2024-05-03 | 2025-11-06 | Kite Pharma, Inc. | Récepteurs chimériques se liant à cll-1 et leurs méthodes d'utilisation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (fr) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Cellules presentant l'antigene, procede de preparation et d'utilisation dans les vaccins contre le cancer |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/fr not_active Ceased
- 2008-01-03 HR HR20110899T patent/HRP20110899T1/hr unknown
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
- 2008-01-03 EP EP08701232A patent/EP2102331B1/fr active Active
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE522600T1 (de) | 2011-09-15 |
| AU2008203730B2 (en) | 2013-11-07 |
| EP2102331A1 (fr) | 2009-09-23 |
| ES2372713T3 (es) | 2012-01-25 |
| JP5452231B2 (ja) | 2014-03-26 |
| US10023839B2 (en) | 2018-07-17 |
| AU2008203730A1 (en) | 2008-07-10 |
| JP2010514455A (ja) | 2010-05-06 |
| GB0700058D0 (en) | 2007-02-07 |
| EP2102331B1 (fr) | 2011-08-31 |
| CY1112668T1 (el) | 2016-02-10 |
| HRP20110899T1 (hr) | 2011-12-31 |
| DK2102331T3 (da) | 2011-10-17 |
| PT2102331E (pt) | 2011-12-19 |
| WO2008081035A1 (fr) | 2008-07-10 |
| SI2102331T1 (sl) | 2012-01-31 |
| US20180036397A1 (en) | 2018-02-08 |
| US20100092498A1 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2102331T3 (pl) | Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+ | |
| Zom et al. | Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates | |
| Vacchelli et al. | Trial watch: Peptide vaccines in cancer therapy | |
| Kumai et al. | Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses | |
| Melief et al. | Therapeutic cancer vaccines | |
| Seledtsov et al. | Clinically feasible approaches to potentiating cancer cell-based immunotherapies | |
| JP2010514455A5 (fr) | ||
| EA202190587A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| BR112012023692A2 (pt) | imunoterapias contra vários tumores, incluindo câncer gastrointestinal e gástrico | |
| EA201071297A1 (ru) | Новые и действенные пептиды мнс ii класса, полученные из сурвивина | |
| MX338294B (es) | Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales. | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| CL2019003423A1 (es) | Nuevos péptidos (seq id n°378), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| Elster et al. | Dendritic cell vaccines: A review of recent developments and their potential pediatric application | |
| JP2015512866A5 (fr) | ||
| CY1114912T1 (el) | Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου | |
| Arina et al. | Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1–resistant tumors leading to tumor eradication | |
| Shen et al. | Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide | |
| JP2018522880A5 (fr) | ||
| Masuko et al. | Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy | |
| Barr et al. | Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer | |
| MX2020011793A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| Yang et al. | HCA587 protein vaccine induces specific antitumor immunity mediated by CD4+ T-cells expressing granzyme B in a mouse model of melanoma | |
| Izgi et al. | Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice | |
| US20160235827A1 (en) | Placental compositions for stimulation of immunity to pd-l1 |